IQVIA and Medera have formed a strategic collaboration to advance cardiac gene therapy and drug discovery. This partnership strengthens efforts in cardiac gene therapy development and innovation.
In addition to this, IQVIA will be able to integrate its worldwide platform for conducting clinical trials with the research platform of Medera. The research platforms include Sardocor and Novoheart, which will assist in developing cardiac gene therapies & drugs for drug discovery programs.
Sardocor is a company that is engaged in the development of gene therapies in order to treat cardiovascular diseases. This company will greatly profit from the experience of IQVIA in regulations and clinical trials. Thus, the collaboration ensures the development of the first-in-human AAV gene therapy projects approved by the FDA. In addition, IQVIA will help recruit patients and collect quality data. In addition, it will facilitate the process of submission and applications for the FDA designation program.
“By combining IQVIA’s global expertise with Medera’s mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster,” said Ronald Li, Co-Founder, Chairman & CEO of Medera. “This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation.”
Advancing Human-Based Drug Discovery and Cardiac Innovation
On the other hand, Novoheart’s ability to discover drugs using human technology keeps improving. The mini-Heart technology is a better option than conventional animal testing. Moreover, the mini-Heart technology assists in creating disease models and drug screening. In addition, it will help secure an IND and Fast Track designation through mini-Heart technology. Novoheart can now use the technology in various organ systems. This helps it meet the FDA Modernization Act 2.0 criteria.
This alliance will further enhance innovations in cardiac gene therapy and human drug discovery. Both companies strive to provide safer and better therapies for their patients. Additionally, they aim to cut down development times. In summary, this alliance is a major milestone in the field of cardiovascular gene therapy and drug discovery.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
